echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Double RNA Note: Drug Source Review 2020

    Double RNA Note: Drug Source Review 2020

    • Last Update: 2020-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020 begins with an RNA virus and ends with an mRNA vaccine.
    The new coronavirus against humans ruthlessly punishes close contact with the most basic way of life in human society, and the mRNA vaccine posts a picture of the surface protrusion protein of the new coronavirus on the streets of the immune system, setting up ten ambushes and eliminating 95% of the uninsed before the patient becomes infected with the new crown.
    two RNAs, one after a thousand years of practice and one that uses modern technology to speed, this year's fight represents by far the highest level of human competition against natural disasters.
    's success in the pharmaceutical industry has made it hard to feed, but there is still good progress in several areas between breathing.
    to date, the FDA has approved 48 new drugs, including the small molecule RNA regulatory drug Evrysdi, the first HMT inhibitor Tazverik, the first video game therapy EndeavorRx, the third RNAi drug Oxlumo, the ADC drug Blenrep, Trodelvy and other highly innovative drugs.
    Drug Source Analysis 1. Defining the New Coronavirus for 2020 Last winter vacation my daughter applied for a scholarship wrote a short essay comparing the situation of different segments of the United States in 1920 and 2020 after the emergence of new technological innovations, pointing out that the 20th century and 100 years ago "Roaring Twenties" have striking similarities.
    she can't predict is that more striking similarities are still to come, and in a few months the whole world will repeat a century-old plague 100 years ago.
    Medical personnel and the pharmaceutical industry as the main force naturally go all out, this year's basic research, new drug project selection, clinical trials, production supply chain all with the new crown as the center, all related to virus replication, immune response related to the new drugs and old drugs are involved in the anti-new crown front.
    , a new technology that has been in question for years, the mRNA vaccine, became a superhero to save the world's health and economy.
    first reported at the beginning of the year, and its genetic sequence was released in January.
    pharmaceutical companies with hammers in their hands immediately began to figure out how to hit the nail, including the mRNA companies Moderna and BioNTech, which had been waiting to be used.
    of course other vaccine manufacturers are also actively involved in the fight, including inactivated viruses, DNA vaccines, and even tobacco expression vaccines.
    and Glaxo, the world's most established vaccine makers, have been passive, publicly questioning the possibility of producing a vaccine within a year or two.
    in fact, before the new crown became a global pandemic, pharmaceutical companies in Europe and the United States generally look across the shore.
    is a matter of concern, is happening on the other side of the ocean, and second, many people think that public health technology such as isolation tracking will be the same as SARS control of the outbreak.
    new crown is considered a fleeting market, the new drug investment will not pay off.
    found that a large number of disease-free infections and high-temperature areas did not reduce infection rates, making people realize that the virus is completely different from SARS and that drug intervention is necessary to stop.
    in addition to the antibody drugs tailored to the new crown has been used, more in the clinical screening of some related old drugs to solve the urgent need.
    Wuhan virus because of the near-water platform in January screened seven drugs that may have broad-spectrum antiviral activity, found that the old drug hydroxychloroquine and Ebola drug Redsyvir infected Vero cells in the new crown the best effect.
    hydroxychloroquine, which has a long history, is cheap and easy to get into multiple clinical trials, French doctors have been the first to announce positive results for a small clinical trial designed to be rough, to the world's euphoria.
    several large clinical studies later proved that the drug did not help much.
    fda once allowed emergency use of hydroxychloroquine for new coronary therapy, but it was withdrawn.
    Redsiwell was given the best hope because of his relatively clear sense of the system, coupled with some positive results from earlier non-controlled trials, and was once nicknamed "the hope of the people", but then China's phase III clinical trial failed.
    although the trial was terminated early because of the patient's entry problems, it was not a great disappointment that hundreds of people had joined the group, reducing viral load and improving prognosto signals a little bit.
    the U.S. government-led trial, which neared the end of the trial, changed the first-level endpoint to a relatively easy time to improve symptoms, showing some benefit in a large controlled trial for the first time gave the world some comfort.
    But a so-called large- and simple trial by the WHO later found that Redsyvir not only failed to reduce mortality, but also had no effect on the time it took to improve symptoms, questioning whether the drug was an overcharged Mr. Nan Guo.
    had an opportunity to clarify The efficacy of Redsiway, but did not join the control group in two so-called Phase III clinical trials involving 4,000 people.
    results wasted valuable clinical resources and time and did nothing to define the efficacy of Redsiway.
    scientists also began the first basic study of the new crown infection, the life cycle of the new crown, the target of each protein, the impact on different tissues quickly have a clear understanding.
    of patients with new crowns have no symptoms or self-healing, and only about 10% of patients suffer from severe illness due to an out-of-control immune response.
    numerous studies have shown that type 1 interferon secretion disorders or auto interferon antibodies are the main immunologic deficiencies, but large-scale tests at the WHO have shown that beta interferon therapy is not helpful, although inhalation of beta interferon by a small Company in the UK has some early effect.
    cytokine storms represented by IL6 in severely ill patients are naturally reminiscent of the successful experience of CAR-T therapy CRS, and unfortunately the phase III clinical failures of IL-6 and IL6-recessed antibody drugs.
    other highly selective immunosuppressive drugs such as JAK and BTK inhibitors also produced only ambiguous treatment results.
    is a broad-spectrum immunosuppressive old drug, Symesong, which has been shown to reduce mortality by 20 percent in large Phase III clinics, and is the only new crown drug with publicly available data showing survival benefits.
    CD24-Fc drug was acquired by Mercadon because it showed some efficacy in Phase III clinical trials.
    Lilly and Regeneratives used their own antibody technology platforms to quickly develop new coronary S protein antibodies and antibody cocktails, but even a few grams of high doses only worked in early patients.
    both products are allowed for emergency use, they are only complementary to the control of the new crown because of their general efficacy and limited availability.
    Although most new crown drug development failed, but the development of antiviral drugs would not have been easy, control cytokine storm is the pharmaceutical industry for many years of weakness, sepsis and other diseases are still a long time to attack.
    that so many drugs can be tested in a short period of time to prove ineffective is not a small achievement, reflecting the high efficiency of the entire chain of new drug development.
    10 months, two vaccines have been designed, screened, and delivered to the world to show the strength of pharmaceutical industry technology, support facilities, and organizational resources, from design, screening, to large-scale trials of 34,000 people.
    2. Other new drug developments in turbulent times 2.1. One of ADC's major events this year has been the re-emergence of ADC drugs.
    ADC has been a major strategy for expanding treatment windows for highly toxic drugs for many years because of its clear design, but the difficult, theoretically existing windows can easily disappear rapidly in complex operations.
    ADC pioneers and cancer giants like Roche have announced that the field is in a pile and ready to quit.
    but with the huge success of Enhertu and several new targets such as TRAP2 ADC, the field has made a high-profile comeback this year.
    not only have two new ADC drugs on the market, but big drug companies have also generously donated to buy ADC assets.
    Gilead's $21 billion acquisition of IMMU, Mercedon's $7 billion acquisition of two ADC assets, BI's $1.4 billion acquisition of NBE, folic acid-controlled drug ADC drug STRO-002 may be the right name for this ancient target, improve the treatment of ovarian cancer.
    2.2. Aducanumab's biggest suspense in the pharmaceutical industry right now is the powdered protein antibody Adu, which, if marketed, could become a rare overweight pound drug, despite its controversial efficacy.
    Adu had already failed two phase III clinical sessions and should have been as gently gone as other powdered protein drugs.
    , however, 100 health submitted a new drug listing application based on an analysis of additional data, and the FDA's central drug review agency publicly gave the drug a falsely named high evaluation.
    this unusual move once led experts to believe that the product would become the second Exondys51, saying you can do it, you can't do it.
    the FDA's external panel of experts gave the product an 8:1 objection, and consumer groups recently asked the FDA director to stop the department's head.
    the FDA still has little chance of approving Adu in the face of such a strong reaction, Baijian has found another way to fund the development of Sage neurosteroid drugs.
    2.3. The hottest technology in small molecule drugs is protein-induced degradation, and many large companies have joined the competition in this field, and the degradation process has expanded from in-cell proteins to membrane proteins and extracellal proteins.
    ARV-110, Arvinas's first drug, released some early data this year, and although the efficacy signals are very general, there are no unintended toxic side effects.
    is a heart-stopping pill for a whole new treatment, with serious side effects such as the oncology that made its debut that year and CRS in CAR-T therapy likely to occur on PROTAC.
    popular target for small molecules is Kras.
    this old drug-infested target became technically feasible because of recent breakthroughs, and at the beginning of the year Mercedon joined forces with Otorasib, the pioneering drug, to gain FDA breakthrough drug status.
    Kras inhibitors have been shorted by some investors because of their unstable performance and short response times on different tumors, but Mirati's surge this year, according to adagrasib data, suggests that believers are also in large numbers.
    2.4. In addition to advances in traditional small molecules, antibody drugs and relatively new treatments such as RNAi and ASO, the most important new treatment this year is the mRNA vaccine.
    technology is a legendary pie, what taste, whether there is taste has been questioned.
    the emergence of the new crown has greatly accelerated the development of this technology, of course, mRNA did not disappoint everyone.
    many people have high hopes for these products, Moderna executives, who know them best, are selling stocks collectively.
    should say that the last two vaccines are far more effective than experts expected.
    new treatment is EndeavorRx, a video game for ADHD treatments, although not through traditional new drug approval channels.
    human brain is a physical and chemical signal processing system, other inputs can also affect the function of the system.
    is an innovation to develop video games, a welcome form of entertainment for people with ADHD, into new treatments that meet FDA approval standards.
    2.5. An important event for EQRx this year is EQRx, supported by prominent drugmaker Alexis Borisy in top VCs including ARCH and GV, and if ordinary people come up with this idea it will most likely be considered the wrong age, but this is an industry where who does more than what is more important.
    drugmaker, which looks like the me-too model, aims to lower drug prices rather than develop new, higher-quality drugs.
    prices of new drugs have reached a point where governments must find a way to address them, and the pharmaceutical industry's self-correction may avoid more deadly regulation.
    , the decline in returns for original innovative drugs will reduce investor interest, regardless of the intervention.
    you spend a lot of time and resources to develop cheap 10th PD-1 drugs to force K drugs to reduce prices is better than directly limit drug prices.
    2020 all the world's activities are centered on the new crown, new drug research and development is no exception.
    proud that the pharmaceutical industry, which has been at the bottom of the credibility polls for many years, has developed a highly effective vaccine within 11 months, which will greatly accelerate the pace of social and economic activity returning to normal.
    this aspect shows that science and technology are the first productive forces, on the other hand, it also shows that if the sense of urgency is sufficient to find new drugs, there is still room for substantial improvement.
    this evented autumn is coming to an end, hoping that by 2021 everything will return to normal and that fighting the new crown will no longer be the main theme of the pharmaceutical industry.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.